Polyrizon Ltd. Ordinary Shares Market Cap ($11.88 Million)
Market Cap & Net Worth: Polyrizon Ltd. Ordinary Shares (PLRZ)
Polyrizon Ltd. Ordinary Shares market cap. Polyrizon Ltd. Ordinary Shares (NASDAQ:PLRZ) has a market capitalization of $11.88 Million ($11.88 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26470 globally and #5538 in its home market, demonstrating a 27.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Polyrizon Ltd. Ordinary Shares's stock price $11.41 by its total outstanding shares 1041677 (1.04 Million). Also see PLRZ operating cash flow for how efficiently the company converts equity into cash flow.
Polyrizon Ltd. Ordinary Shares Market Cap History (2024–2026)
Polyrizon Ltd. Ordinary Shares market cap history from 2024 to 2026. Data shows growth from $2.26 Million to $11.88 Million (169.42% CAGR). Check current stock price of Polyrizon Ltd. Ordinary Shares for real-time trading data and today's change.
Index Memberships
Polyrizon Ltd. Ordinary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #738 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2417 of 3165 |
Weight: Polyrizon Ltd. Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Polyrizon Ltd. Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Polyrizon Ltd. Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Polyrizon Ltd. Ordinary Shares to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PLRZ by Market Capitalization
Companies near Polyrizon Ltd. Ordinary Shares in the global market cap rankings as of November 4, 2026. Also see total assets of Polyrizon Ltd. Ordinary Shares for a full breakdown of the balance sheet.
Key companies related to Polyrizon Ltd. Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Polyrizon Ltd. Ordinary Shares (2024–2026)
Market capitalization of Polyrizon Ltd. Ordinary Shares from 2024 to today. Between 2024 and today, Polyrizon Ltd. Ordinary Shares's market cap moved from $2.26 Million to $ 11.88 Million, with a yearly change of 169.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.88 Million | +34.33% |
| 2025 | $8.84 Million | +291.24% |
| 2024 | $2.26 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Polyrizon Ltd. Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.88 Million USD |
| MoneyControl | $11.88 Million USD |
| MarketWatch | $11.88 Million USD |
| marketcap.company | $11.88 Million USD |
| Reuters | $11.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nas… Read more